SAVA Cassava Sciences Inc.

48.51
+4.56  (+10%)
Previous Close 43.95
Open 43.97
52 Week Low 6.7
52 Week High 146.16
Market Cap $1,941,112,854
Shares 40,014,695
Float 37,922,725
Enterprise Value $1,480,672,845
Volume 6,055,334
Av. Daily Volume 8,431,097
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Simufilam (PTI-125)
Alzheimer’s disease
Phase 2
Phase 2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Latest News

  1. AUSTIN, Texas, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that management will present at H.C. Wainwright's 23rd Annual Global Investment Conference, a virtual event that takes place September 13-15, 2021.

    Cassava Sciences' presentation is a ‘fireside chat' with Vernon T. Bernardino, PhD., Managing Director, Biotechnology Equity Research, at H.C. Wainwright.

    Event details follow: 
    Date:Monday, September 13th
    Time:7:00 a.m. Eastern Time
    Webcast:https://www.CassavaSciences.com/company-presentations

    Cassava Sciences' fireside chat will be available for replay for 90 days following the conference on www.CassavaSciences.com in the ‘Investors…

    AUSTIN, Texas, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that management will present at H.C. Wainwright's 23rd Annual Global Investment Conference, a virtual event that takes place September 13-15, 2021.

    Cassava Sciences' presentation is a ‘fireside chat' with Vernon T. Bernardino, PhD., Managing Director, Biotechnology Equity Research, at H.C. Wainwright.

    Event details follow: 
    Date:Monday, September 13th
    Time:7:00 a.m. Eastern Time
    Webcast:https://www.CassavaSciences.com/company-presentations

    Cassava Sciences' fireside chat will be available for replay for 90 days following the conference on www.CassavaSciences.com in the ‘Investors' section.

    About Alzheimer's Disease

    Alzheimer's disease is a progressive brain disorder that destroys memory and thinking skills. As of 2020, there were approximately 50 million people worldwide living with dementia, a figure expected to increase to over 150 million by 2050.1 The annual global cost of dementia is now above $1 trillion, according to Alzheimer's Disease International, a charitable organization.

    About Cassava Sciences, Inc.

    Cassava Sciences' mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer's disease.

    Simufilam and SavaDx were both developed in-house. Cassava Sciences owns worldwide development and commercial rights to its research programs in Alzheimer's disease, and related technologies, without royalty obligations to any third party.

    For more information, please visit https://www.CassavaSciences.com

    Contact Information:

    Eric Schoen, Chief Financial Officer

    Cassava Sciences, Inc.

    eschoen@CassavaSciences.com

    (512) 501-2450

    1 Alzheimer's Disease International, Dementia Statistics, available on-line and accessed September 8, 2021.

     



    Primary Logo

    View Full Article Hide Full Article
  2. AUSTIN, Texas, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a biotechnology company focused on Alzheimer's disease, today released a public statement regarding recent allegations made against the Company.

    "Let me be very clear: I think these allegations are false," said Remi Barbier, President & CEO. "The allegations claim our science is improbable, unexpected and unique to Cassava Sciences, and therefore it's all an elaborate fraud. By these criteria, all drug innovations are fraudulent. We intend to vigorously defend ourselves and our stakeholders against false and misleading allegations."

    Cassava Sciences' full public statement is now available as an audio file made by Remi Barbier, President & CEO, or as a…

    AUSTIN, Texas, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a biotechnology company focused on Alzheimer's disease, today released a public statement regarding recent allegations made against the Company.

    "Let me be very clear: I think these allegations are false," said Remi Barbier, President & CEO. "The allegations claim our science is improbable, unexpected and unique to Cassava Sciences, and therefore it's all an elaborate fraud. By these criteria, all drug innovations are fraudulent. We intend to vigorously defend ourselves and our stakeholders against false and misleading allegations."

    Cassava Sciences' full public statement is now available as an audio file made by Remi Barbier, President & CEO, or as a written transcript. Both are intended to be similar in content and are available on-line on the links below:

    Audio File:



    http://public.viavid.com/index.php?id=146489



    Written Response:



    ‘Investors' page of the Company's website

    https://www.CassavaSciences.com

    The Audio File will also be archived on the ‘Investors' page of the Company's website: https://www.CassavaSciences.com.

    About Cassava Sciences, Inc.

    Cassava Sciences' mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer's disease. For more information, please visit: https://www.CassavaSciences.com.

    For More Information Contact:

    Eric Schoen, Chief Financial Officer

    eschoen@CassavaSciences.com

    (512) 501-2450

    Cautionary Note Regarding Forward-Looking Statements:

    This news release includes forward looking statements including but not limited to those regarding the timing of the initiation and subsequent progress of our pivotal Phase 3 trial and its likelihood of success, the timing of announcement of the results of our open label study, the FDA response to the Citizen's Petition, the initiation and progression of the CUNY scientific inquiry and the publication of its results, and the restoration of scientific reputations. 

    Drug development involves a high degree of risk, and historically only a small number of research and development programs result in commercialization of a product. Clinical results from our earlier-stage clinical trials may not be indicative of full results or results from later-stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or any scientific data we present or publish. Such statements are based largely on our current expectations and projections about future events.

    Such statements speak only as of the date of this news release and are subject to a number of risks, uncertainties and assumptions, including, but not limited to, those risks relating to the ability to conduct or complete clinical studies on expected timelines, to demonstrate the specificity, safety, efficacy or potential health benefits of our product candidates, the severity and duration of health care precautions given the COVID-19 pandemic, any unanticipated impacts of the pandemic on our business operations, and including those described in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2020 and future reports to be filed with the SEC. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from expectations in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking statements and events discussed in this news release are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Except as required by law, we disclaim any intention or responsibility for updating or revising any forward-looking statements contained in this news release.

    For further information regarding these and other risks related to our business, investors should consult our filings with the SEC, which are available on the SEC's website at www.sec.gov.



    Primary Logo

    View Full Article Hide Full Article
  3. AUSTIN, Texas, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a biotechnology company focused on Alzheimer's disease, today released a statement regarding plasma p-tau analysis from a previously disclosed randomized, controlled Phase 2b clinical study in patients with Alzheimer's disease. For this study, Cassava Sciences contracted with Quanterix Corp., a highly regarded, independent laboratory, to perform sample testing on blinded samples.

    The Phase 2b clinical study was conducted by Cassava Sciences. Quanterix' sole responsibility with regard to this clinical study was to perform sample testing, specifically, to measure levels of p-tau in plasma samples collected from study subjects.

    "To ensure data integrity…

    AUSTIN, Texas, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a biotechnology company focused on Alzheimer's disease, today released a statement regarding plasma p-tau analysis from a previously disclosed randomized, controlled Phase 2b clinical study in patients with Alzheimer's disease. For this study, Cassava Sciences contracted with Quanterix Corp., a highly regarded, independent laboratory, to perform sample testing on blinded samples.

    The Phase 2b clinical study was conducted by Cassava Sciences. Quanterix' sole responsibility with regard to this clinical study was to perform sample testing, specifically, to measure levels of p-tau in plasma samples collected from study subjects.

    "To ensure data integrity, it is standard industry practice to keep separate the people who generate the data from the people who analyze the data," said Remi Barbier, President & CEO. "That certainly was the case here. Anything different is a distortion of the facts."

    Quanterix' sample testing was conducted entirely by its employees. Quanterix' employees were blind to treatment group, i.e., they did not know which samples were from placebo, or simufilam-treated patients. Quanterix conducted sample testing, then sent raw data to Cassava Sciences for analysis of treatment effects. Eventually, Cassava Sciences presented these data in a poster presentation at the Alzheimer's Association International Conference (AAIC) in July 2021. In keeping with scientific authorship guidelines, prior to submitting the abstract to AAIC, Cassava Sciences received permission from Quanterix to include its lab personnel in the author list.

    Cassava Sciences is aware of allegations that are being made by a party that yesterday admitted it holds a short position in the Company's stock. (A short position allows an investor to profit from a drop in the Company's stock price.) Cassava Sciences believes claims made by this party regarding scientific integrity are false and misleading. The Company stands behind its science, its scientists and its scientific collaborators, and is responding to ensure the facts are known and respected.

    About Cassava Sciences, Inc.

    Cassava Sciences' mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer's disease. For more information, please visit: https://www.CassavaSciences.com.

    For More Information Contact:

    Eric Schoen, Chief Financial Officer

    eschoen@CassavaSciences.com, or (512) 501-2450

    Cautionary Note Regarding Forward-Looking Statements: Drug development involves a high degree of risk, and historically only a small number of research and development programs result in commercialization of a product. Clinical results from our earlier-stage clinical trials may not be indicative of full results or results from later-stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or any scientific data we present or publish. Such statements are based largely on our current expectations and projections about future events.

    Such statements speak only as of the date of this news release and are subject to a number of risks, uncertainties and assumptions, including, but not limited to, those risks relating to the ability to conduct or complete clinical studies on expected timelines, to demonstrate the specificity, safety, efficacy or potential health benefits of our product candidates, the severity and duration of health care precautions given the COVID-19 pandemic, any unanticipated impacts of the pandemic on our business operations, and including those described in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2020 and future reports to be filed with the SEC. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from expectations in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking statements and events discussed in this news release are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Except as required by law, we disclaim any intention or responsibility for updating or revising any forward-looking statements contained in this news release.

    For further information regarding these and other risks related to our business, investors should consult our filings with the SEC, which are available on the SEC's website at www.sec.gov.

     



    Primary Logo

    View Full Article Hide Full Article
  4. Boston, Massachusetts--(Newsfile Corp. - August 26, 2021) -  Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA), a drug development company.

    On August 25, 2021, Bloomberg reported that shares of Cassava were down 31% "after a lawyer sought to stop studies of the biotech company's experimental treatment for Alzheimer's disease." According to Bloomberg, "a citizen petition from a former Securities and Exchange Commission enforcement lawyer questioned the quality and integrity of the results from the more than 20-year-old company with no products on the market." Further, "[t]e FDA says it is reviewing the petition…

    Boston, Massachusetts--(Newsfile Corp. - August 26, 2021) -  Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA), a drug development company.

    On August 25, 2021, Bloomberg reported that shares of Cassava were down 31% "after a lawyer sought to stop studies of the biotech company's experimental treatment for Alzheimer's disease." According to Bloomberg, "a citizen petition from a former Securities and Exchange Commission enforcement lawyer questioned the quality and integrity of the results from the more than 20-year-old company with no products on the market." Further, "[t]e FDA says it is reviewing the petition and will respond directly to the petitioner." Shares of Cassava closed at $80.86 per share, down from its close of $117.83 per share on August 24, on heavy volume.

    On August 26, 2021, shares Cassava traded down another 13% to approximately $70.18 per share by the midday.

    If you purchased Cassava securities, sustained substantial losses and would like more information about the investigation, or have information concerning this investigation, please click here: Shareholder Contact | Berman Tabacco.

    Berman Tabacco is a national law firm representing institutions and individuals in lawsuits, seeking to recoup losses caused by corporate and board misconduct and violations of the securities and antitrust laws. The firm has offices in Boston, Massachusetts and San Francisco, California.

    This notice may constitute attorney advertising.

    Contact:

    Jay Eng, Esq.
    (800) 516-9926
    Email: law@bermantabacco.com

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/94555

    View Full Article Hide Full Article
  5. Boston, Massachusetts--(Newsfile Corp. - August 25, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA), a drug development company.

    On August 25, 2021, Bloomberg reported that shares of Cassava were down over 20% in pre-market trading "after a lawyer asked the FDA to halt the company's clinical trials of an experimental drug, citing concerns about the quality of past studies of the medicine." According to Bloomberg, a citizen petition dated August 18, 2021 "was posted on a U.S. government website Monday seeking a halt to trials of the drug Simufilam for Alzheimer's disease."

    If you purchased Cassava securities…

    Boston, Massachusetts--(Newsfile Corp. - August 25, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA), a drug development company.

    On August 25, 2021, Bloomberg reported that shares of Cassava were down over 20% in pre-market trading "after a lawyer asked the FDA to halt the company's clinical trials of an experimental drug, citing concerns about the quality of past studies of the medicine." According to Bloomberg, a citizen petition dated August 18, 2021 "was posted on a U.S. government website Monday seeking a halt to trials of the drug Simufilam for Alzheimer's disease."

    If you purchased Cassava securities, sustained substantial losses and would like more information about the investigation, or have information concerning this investigation, please visit: https://www.bermantabacco.com/case/cassava-sciences-inc/.

    Berman Tabacco is a national law firm representing institutions and individuals in lawsuits, seeking to recoup losses caused by corporate and board misconduct and violations of the securities and antitrust laws. The firm has offices in Boston, Massachusetts and San Francisco, California.

    This notice may constitute attorney advertising.

    Contact:
    Jay Eng, Esq.
    (800) 516-9926
    Email: law@bermantabacco.com

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/94365

    View Full Article Hide Full Article
View All Cassava Sciences Inc. News